Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Time to Buy?

Key Points

• Seaport Therapeutics shares reached a new 52-week high of $23.34 and were recently trading at $23.09, up 3.4% from the prior close.
• Analyst views are mixed, with five Buy, three Hold, and one Sell rating; the average rating is Hold, while the average price target of $38.40 implies potential upside.
• The company reported a quarterly loss of $1.78 per share, missing estimates by $1.07, and analysts expect a full-year loss of approximately $4.33 per share. A director also purchased 13,000 shares at an average price of $18.14.

Seaport Therapeutics, Inc. (NASDAQ:SPTX - Get Free Report)'s stock price reached a new 52-week high on Thursday . The company traded as high as $23.34 and last traded at $23.09, with a volume of 106561 shares. The stock had previously closed at $22.34.

Analysts Set New Price Targets

SPTX has been the topic of several recent research reports. Wolfe Research started coverage on shares of Seaport Therapeutics in a report on Tuesday, July 7th. They issued a "hold" rating on the stock. Zacks Research upgraded Seaport Therapeutics to a "hold" rating in a research note on Wednesday, May 27th. Stifel Nicolaus started coverage on Seaport Therapeutics in a research report on Tuesday, May 26th. They set a "buy" rating and a $30.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Seaport Therapeutics in a report on Tuesday. Finally, Seaport Research Partners set a $50.00 price objective on shares of Seaport Therapeutics in a research note on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Seaport Therapeutics currently has an average rating of "Hold" and an average target price of $38.40.

Seaport Therapeutics Stock Up 3.4%

The stock's fifty day moving average is $19.60.

Seaport Therapeutics (NASDAQ:SPTX - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($1.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($1.07). On average, research analysts anticipate that Seaport Therapeutics, Inc. will post -4.33 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Robert J. Hombach acquired 13,000 shares of Seaport Therapeutics stock in a transaction on Monday, June 22nd. The stock was bought at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the transaction, the director owned 13,000 shares of the company's stock, valued at approximately $235,820. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Seaport Therapeutics Company Profile

Seaport Therapeutics Inc is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc is based in BOSTON.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source